Date: 2016-12-02
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Ovid Therapeutics (USA - NY)
Product: OV101 (gaboxadol - 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol)
Action
mechanism: GABA receptor agonist. OV101 is a delta (?)-selective GABA-A receptor agonist and is being developed to help restore tonic inhibition in patients living with Angelman syndrome. OV101 has been shown in pre-clinical models to normalize tonic inhibition and influence sleep, motor control and cognition, increasing the possibility of improved outcomes for patients.
Disease: Angelman Syndrome
Therapeutic area: Rare diseases - Genetic diseases - Neurological diseases
Country: USA
Trial
details: The purpose of the study is to assess the safety and tolerability of oral OV101 (gaboxadol) in adult subjects with Angelman syndrome. In addition, several exploratory efficacy outcome measures will be investigated. (NCT02996305)
Latest
news: * On December 2, 2016, a Phase 2 trial sponsored by Ovid Therapeuticso was published on the NIH website ClinicalTrials.gov for OV101 (gaboxadol - 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol) and is currently recruiting participants.
